Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study
Isala
776 participants
Sep 1, 2023
INTERVENTIONAL
Conditions
Summary
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Gradual shortening of infusion times
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06031233